Form 4: Arcutis Biotherapeutics Director Howard G. Welgus Sells 10,000 Shares

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) common stock on October 1, 2024, at a weighted average price of $9.2616 per share, according to a Form 4 filing with the SEC.

Summary

• On October 1, 2024, Howard G. Welgus, a director of Arcutis Biotherapeutics, Inc. (ARQT), sold 10,000 shares of common stock.
• The sale was executed under a pre-arranged 10b5-1 trading plan.
• The shares were sold at a weighted average price of $9.2616, with individual prices ranging from $9.22 to $9.4138.
• Following the transaction, Welgus directly owns 181,944 shares of Arcutis Biotherapeutics.
• The sale was reported on a Form 4 filing with the Securities and Exchange Commission on October 3, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan and doesn't necessarily reflect a change in the director's view of the company's prospects.

Industry Context

Sales by company insiders are a common occurrence and are often related to personal financial planning. It is important to consider the overall trend of insider transactions and the company's performance when evaluating the significance of this sale.

Stakeholder Impact

• The sale of shares by a director could potentially create short-term negative sentiment among shareholders, although the impact is likely to be minimal given the pre-planned nature of the transaction.

Key Dates